Loading...
  • drugs
  • The amount of an aminoglycoside given per dose depends on a variety of factors, including kidney function, other drugs the person may be taking, age, and weight. (labtestsonline.org)
  • Although the ototoxic effects of aminoglycosides are well documented, this class of drugs is still widely used today. (medscape.com)
  • Of all ototoxic drugs, the aminoglycosides are the most vestibulotoxic, although they vary greatly in their differential effects on the vestibular and cochlear systems. (medscape.com)
  • More frequent aminoglycoside monitoring may be performed for people with impaired kidney function (renal insufficiency) and for people who have an increased risk of toxic side effects, such as those taking other drugs known to adversely affect hearing and the kidneys (ototoxic or nephrotoxic). (labcorp.com)
  • species
  • It differs from most Burkholderia species in that it is often susceptible to aminoglycosides, but not polymyxin B. Many isolates have been found to be catalase positive. (wikipedia.org)
  • kidney
  • Pre-existing medical conditions-such as kidney disease, eighth cranial nerve disease, myasthenia gravis , and Parkinson's disease-should be discussed prior to taking any aminoglycosides. (encyclopedia.com)
  • Though kidney damage caused by aminoglycosides is usually reversible, hearing and/or balance loss is frequently permanent. (labtestsonline.org)
  • dose
  • When a dose of one of the aminoglycosides is given, the level typically rises in the blood to a peak concentration and then falls over time to a lower (trough) concentration. (labcorp.com)
  • Mechanisms
  • Aminoglycosides, among other potential mechanisms of action, interfere with the proofreading process, causing increased rate of error in synthesis with premature termination. (wikipedia.org)
  • vein
  • Aminoglycosides are not well absorbed by the digestive system so they are typically be administered either through a needle into a vein ( intravenously, IV ) or by injection into a muscle ( intramuscularly, IM ). (labtestsonline.org)
  • multiple
  • Although there are multiple studies documenting the use of aminoglycosides in obese patients, there is a lack of data specifically in the morbidly obese population, which has been identified as greater than or equal to 190% of IBW or a body mass index (BMI) of greater than or equal to 40 kg/m 2 [ 20 , 21 ]. (hindawi.com)
  • drug
  • For interval dosing, testing is usually ordered after 2 to 4 doses of the aminoglycoside have been given and when the drug is expected to have reached a relatively stable level in the blood (steady state). (labcorp.com)
  • described obese patients having an altered glomerular filtration rate and increased aminoglycoside drug clearance [ 20 ]. (hindawi.com)